Introduction: The management of cervical cancer is well established and effective when initiated early; however, in the state of Pará, mortality from this neoplasm remains high, highlighting significant regional disparities and delays in diagnosis. Objectives: To analyze and compare cervical cancer treatment data in Pará and Brazil from 2019 to 2023, focusing on regional disparities in access, care, and outcomes. Methods: A descriptive epidemiological study was conducted using secondary data from the Oncology Observatory, including chemotherapy and radiotherapy APACs (Authorization of Outpatient Procedures) with ICD-10 code C53 from SIA/SUS (Datasus) and Hospital Cancer Registries (INCA). The 2019–2023 period was selected to capture pre-pandemic and post-pandemic trends. Results: From 2019 to 2023, Pará lagged behind the national average in timely cervical cancer treatment. In chemotherapy, cases starting after 60 days increased from 70.1% (2019) to 87.6% (2022), with slight improvement in 2023 (82.2%). Treatments initiated within 30 days decreased from 10.2% (2019) to 4.9% (2022), then rose to 7.0% (2023). Nationally, the proportion of patients starting chemotherapy after 60 days ranged from 71.8% to 74.3%, while treatments within 30 days remained between 10.5% and 12.2%. In radiotherapy, Pará recorded delays exceeding 90% annually, with a median wait time of 234 days in 2021, compared to 132 days nationally. Treatment within the municipality of residence was less frequent in Pará (29.7%–38.8%) than in Brazil overall (37.9%–40.4%), indicating decentralization challenges. The ethnic profile in Pará showed an increase in mixed-race patients from 61.7% (2019) to 99.3% (2023), while Black patients decreased from 36.3% to 0% after 2021. White patients ranged from 1.5% to 8.0%, showing a decline, and Asian patients appeared only in 2021 (2.2%). In Brazil, ethnic distribution remained stable, with mixed-race (48.7%–52.3%), white (37.1%–40.2%), Black (5.1%–6.0%), and Asian (4.4%–5.9%) populations. In Pará, chemotherapy from 2019 to 2023 predominantly involved women aged 40–59, with a shift from the 50–59 to the 40–49 age group from 2020 onward, alongside increases among those aged 30–39 and 60–69. Radiotherapy followed a similar pattern, initially peaking in the 50–59 and 60–69 age groups in 2019 and later concentrating among women aged 40–49. Nationally, age distribution was more balanced, with a higher proportion of elderly women receiving treatment. Disease staging in Pará initially showed predominance of stage II, but stages III and IV increased from 2021, accounting for over 56% of chemotherapy cases in 2023, suggesting late diagnosis; nationally, stage III was most frequent. Mortality rates in Pará were higher than the national average, particularly among mixed-race women aged 40–59, whereas nationally, deaths were more ethnically diverse and more common after age 50. Conclusion: The findings highlight major oncology challenges in Pará, including delayed treatment initiation, advanced-stage diagnoses, limited access to care, and racial disparities, all of which contribute to poorer outcomes and higher mortality, underscoring the need for targeted improvements in healthcare delivery and public policy.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
